Ceres Nanosciences

Ceres Nanosciences is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products based on its proprietary Nanotrap® technology, which captures, enriches, and preserves analytes/biomarkers. Early detection of biomarkers, especially low-abundance ones, is crucial for the diagnosis and treatment of diseases such as cancer, heart disease, and infectious diseases, improving patient outcomes and reducing healthcare costs. Ceres has an extensive pipeline of advanced sample collection technologies and diagnostic products funded by federal agency grants and industry collaboration funds. The company's lead product under development is a direct antigen test for Lyme disease diagnosis, expected to be commercially available in 2015.